• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

    10/4/24 4:23:23 PM ET
    $TMDX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TMDX alert in real time by email
    SC 13G/A 1 UnitedStates_13G__TransMedic.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) TransMedics Group Inc (Title of Class of Securities) Common Stock (CUSIP Number) 89377M109 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 89377M109 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b)X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 59,000 (see Item 4) (7) Sole dispositive power 3,498,374 (8) Shared dispositive power 96,685 (see Item 4) (9) Aggregate amount beneficially owned by each reporting person 3,595,059 (see Item 4) (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 10.77% (see Item 4) (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: TransMedics Group Inc Item 1(b) Address of issuer's principal executive offices: 200 Minuteman Road Suite 302 Andover, MA 01810 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 89377M109 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 3,595,059 (b) Percent of class: 10.77% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 3,595,059 (b) Percent of class: 10.77% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 59,000 (iii) Sole power to dispose or to direct the disposition of: 3,498,374 (iv) Shared power to dispose or to direct the disposition of: 96,685 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, including investment companies registered under the Investm* ent Company Act of 1940 and other managed accounts, have the right to receive o* r the power to direct the receipt of dividends from, or the proceeds from the s* ale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, the securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: October 04, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration
    Get the next $TMDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMDX

    DatePrice TargetRatingAnalyst
    12/17/2024$116.00 → $75.00Overweight → Neutral
    Analyst
    11/22/2024Buy → Hold
    Needham
    10/29/2024$200.00 → $125.00Outperform
    Oppenheimer
    10/29/2024$208.00 → $109.00Buy
    Needham
    9/24/2024$200.00Outperform
    Robert W. Baird
    8/21/2024$208.00Buy
    Needham
    6/6/2024$161.00Overweight
    Cantor Fitzgerald
    6/4/2024$151.00Overweight
    Stephens
    More analyst ratings

    $TMDX
    Financials

    Live finance-specific insights

    See more
    • TransMedics Reports First Quarter 2025 Financial Results

      ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565

      5/8/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025

      ANDOVER, Mass., April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domesti

      4/24/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results

      ANDOVER, Mass., Feb. 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2024. Recent Highlights  Total revenue of $121.6 million in the fourth quarter of 2024, a 50% increase compared to the fourth quarter of 2023Total revenue of $441.5 million in the full year of 2024, an 83% increase compared to the full year 2023Generated net income of $

      2/27/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Khayal Tamer I sold $183,967 worth of shares (2,407 units at $76.43), decreasing direct ownership by 6% to 36,042 units (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      3/5/25 4:30:17 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President & CEO Hassanein Waleed H was granted 59,781 shares, increasing direct ownership by 97% to 121,424 units (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      2/26/25 6:16:52 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Financial Officer Hernandez Gerardo was granted 3,521 shares, increasing direct ownership by 28% to 15,984 units (SEC Form 4)

      4 - TransMedics Group, Inc. (0001756262) (Issuer)

      2/26/25 6:15:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TransMedics Reports First Quarter 2025 Financial Results

      ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565

      5/8/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025

      ANDOVER, Mass., April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domesti

      4/24/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      ANDOVER, Mass., April 2, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on March 28, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 1,570 shares of its common stock and an aggregate of 1,043 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4)

      4/2/25 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TransMedics Group downgraded by Analyst with a new price target

      Analyst downgraded TransMedics Group from Overweight to Neutral and set a new price target of $75.00 from $116.00 previously

      12/17/24 8:22:54 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Group downgraded by Needham

      Needham downgraded TransMedics Group from Buy to Hold

      11/22/24 8:05:47 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Oppenheimer reiterated coverage on TransMedics Group with a new price target

      Oppenheimer reiterated coverage of TransMedics Group with a rating of Outperform and set a new price target of $125.00 from $200.00 previously

      10/29/24 7:47:16 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Leadership Updates

    Live Leadership Updates

    See more
    • TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook

      ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025, before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagem

      12/2/24 4:05:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 and S&P MidCap 400: S&P SmallCap 600 constituent The Ensign Group Inc. (NASD: ENSG) will replace Southwestern Energy Co. (NYSE:SWN) in the S&P MidCap 400 and TransMedics Group, Inc. (NASD: TMDX) will replace The Ensign Group in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 1.  S&P MidCap 400 constituent Chesapeake Energy Corp. (NASD: CHK) is acquiring Southwestern Energy in a deal expected to be completed October 1.Curbline Properties Corp. (NYSE:CURB) will be added to the S&P SmallCap 600 effective prior to the open of trading on Tuesda

      9/26/24 6:04:00 PM ET
      $CCRN
      $CHK
      $ENSG
      $SITC
      Professional Services
      Consumer Discretionary
      Oil & Gas Production
      Energy
    • TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary

      ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary. "We are excited to welcome Anil to the TransMedics leadership team," said Waleed Hassanein, MD, President and Chief Executive Officer. "Anil brings a wealth of healthcare industry experience, and his knowledge and counsel will be

      7/26/23 5:09:00 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    SEC Filings

    See more
    • SEC Form 144 filed by TransMedics Group Inc.

      144 - TransMedics Group, Inc. (0001756262) (Subject)

      5/9/25 4:02:59 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by TransMedics Group Inc.

      10-Q - TransMedics Group, Inc. (0001756262) (Filer)

      5/8/25 4:15:56 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TransMedics Group, Inc. (0001756262) (Filer)

      5/8/25 4:05:28 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TMDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      10/7/24 11:37:08 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TransMedics Group Inc.

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      10/4/24 4:23:23 PM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by TransMedics Group Inc. (Amendment)

      SC 13G/A - TransMedics Group, Inc. (0001756262) (Subject)

      2/14/24 6:28:57 AM ET
      $TMDX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care